• Profile
Close

Sacubitril/valsartan vs enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study: sacubitril/valsartan and enalapril on peak VO 2 in patients with heart failure wi

American Heart Journal May 28, 2021

dos Santos MR, de Nazaré Nunes Alves MJ, Jordao CP, et al. - The present study was conducted to correlate sacubitril/valsartan versus enalapril in patients with heart failure with reduced ejection fraction (HFrEF) based on peak oxygen consumption (VO 2 ) and 6-minute walk test (6-MWT). Researchers enrolled a total of 52 individuals with HFrEF with a left ventricular ejection fraction < 40% to receive either sacubitril/valsartan (target dose of 400 mg daily) or enalapril (target dose of 40 mg daily). Cardiopulmonary exercise testing was used to measure peak VO 2. They further conducted a six-minute walk test. The results indicate that sacubitril/valsartan did not substantially improve peak VO 2 or 6-MWT after 12 or 24 weeks in comparison with enalapril in participants with HFrEF.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay